CN101600438B - 疼痛疾病治疗剂 - Google Patents
疼痛疾病治疗剂 Download PDFInfo
- Publication number
- CN101600438B CN101600438B CN2008800039466A CN200880003946A CN101600438B CN 101600438 B CN101600438 B CN 101600438B CN 2008800039466 A CN2008800039466 A CN 2008800039466A CN 200880003946 A CN200880003946 A CN 200880003946A CN 101600438 B CN101600438 B CN 101600438B
- Authority
- CN
- China
- Prior art keywords
- pain
- sialic acid
- neuropathy
- disease
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/02—Acyclic radicals
- C07H7/027—Keto-aldonic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
本发明关于针对非炎症性疼痛疾病的镇痛剂,所述镇痛剂含有唾液酸或其药学可接受的盐作为有效成分。本发明的有效成分唾液酸,对于非炎症性疼痛的神经性疼痛的病理模型动物显示镇痛作用。因此,本发明镇痛剂可用作治疗,例如,三叉神经痛、带状疱疹后神经痛、包埋性神经病变、复杂性局部痛综合症(CRPS)、糖尿病性神经病变,外伤引起的神经障碍、幻肢痛、脊椎损伤后或脑中风后的中枢疼痛,以及药物疗法或放射线治疗法所引起的神经病变等神经性疼痛疾病等非炎症性疼痛疾病的药剂。
Description
技术领域
本发明关于针对非炎症性疼痛疾病的镇痛剂,含有唾液酸或其药学可接受的盐作为有效成分。
背景技术
唾液酸(sialic acid)是神经氨酸酰基衍生物的总称,自然界存在多种唾液酸,其中尤以N-乙酰基神经氨酸(N-acetylneuraminic acid)为最多,其次以N-羟乙酰神经氨酸(N-glycolylneuramic acid)的比例为多。唾液酸作为糖蛋白、糖脂质、糖肽等的构成成分而广泛分布于生物体内,尤其是存在于动物或细菌细胞膜表面,与细胞的特异性辨认机制等相关联,担任重要生物学机能。唾液酸类作为与癌、炎症、免疫、病毒感染、细胞分化、激素受体等有关的物质而在医学及药学上受重视,对于唾液酸(sialic acid)及其衍生物正进行种种研究。
发明人在唾液酸药理作用的多次研究中发现,唾液酸具有特殊镇痛作用。“痛”大略可分为由于组织损伤等产生炎症、释放发痛物质而产生的炎症性疼痛,未伴随该种炎症的生理性痛(侵害性疼痛)以及神经性疼痛。神经性疼痛是起因于中枢神经或末梢神经损伤或机能异常的疼痛,及药物治疗或放射线治疗法引起的神经病变等非炎症性疼痛的总称。除了自发性痛外,神经性疼痛产生针对侵害性刺激的疼痛阈值降低的痛觉过敏反应,或通常不会引起痛觉的触觉刺激所引起的激痛(allodynia)等症状,历经一次病理完成而变成慢性,与炎症性疼痛不同,神经性疼痛是非常难治的。例如,可列举三叉神经痛、带状疱疹后神经痛、包埋性神经病变(entrapment neuropathy)(胸廓出口综合症、腕管综合症、脊柱管狭窄症等)、复杂性局部痛综合症(CRPS)、糖尿病性神经病变(diabetic neuropathy),外伤引起的神经障碍、幻肢痛、脊椎损伤后或脑中风后中枢疼痛等神经性疾病。
现在,使用非甾体镇痛药、非麻醉性镇痛药、麻醉性镇痛药等治 疗炎症性疼痛的方法可说是差不多确立了。但是,对于神经性疼痛等非炎症性疼痛,则虽正进行病理发症机制的解读,但有效治疗药少,需要确立其病理解读及治疗方法。发明人发现,唾液酸对于非炎症性疼痛的病理模型动物有镇痛作用,从而完成本发明。已有关于唾液酸抗炎症作用的报导(专利文献1及2),关于唾液酸对非炎症性镇痛作用则无任何揭露,也没有提示。
[专利文献1]日本特开昭62-145015号公报
[专利文献2]日本特开平1-163125号公报
发明内容
(发明要解决的课题)
本发明目的在于提供针对非炎症性疼痛疾病的镇痛剂,含有唾液酸或其药学可接受的盐作为有效成分。
(用于解决课题的手段)
发明人自唾液酸对于非炎症性疼痛的病理模型动物表现镇痛作用的事实发现,唾液酸可做为针对神经性疼痛等非炎症性疼痛疾病的镇痛剂,从而完成本发明。
(发明效果)
本发明药剂的有效成分唾液酸,对非炎症性疼痛的病理模型动物表现镇痛作用。因此本发明镇痛剂可用作治疗神经性疼痛等非炎症性疼痛疾病的药剂。
具体实施方式
本发明关于针对非炎症性疼痛疾病的镇痛剂,含有唾液酸或其药学可接受的盐作为有效成分。
本发明镇痛剂的有效成分唾液酸,包含其药学可接受的盐,例如与钠、钾等碱金属,钙、镁、钡等碱土金属或铝、锌等金属、有机胺及铵等的盐。这些盐可用已知方法从游离的唾液酸制造,或可以互相变换。已知存在15种以上唾液酸,多数具有N-乙酰基或N-羟基乙酰 基,以及N-酰基或O-酰基,在本发明中任意一种都可以利用。优选自然界存在最多的,可列举代表性唾液酸——N-乙酰基神经氨酸及其药学可接受的盐。上述专利文献1揭露关于N-乙酰基神经氨酸的急性毒性极低而安全。再者,N-乙酰基神经氨酸钠盐的急性毒性试验结果显示其毒性极低。(参照日本专利特公昭63-28411号公报实施例8)。
本发明中,唾液酸的顺-反异构体、光学异构体、构型异构体等立体异构体存在时,或以水合物或配位化合物的状态存在时,本发明也包含其所有的立体异构体、水合物、配位化合物。
本发明唾液酸可与适当的医药用载体或稀释剂组合成医药,可以任何常规方法制剂化,可制成片剂、胶囊剂、粉末剂、液体剂等口服剂,或皮下、静脉、肌肉、直肠、鼻腔给药用的非口服剂。在处方中,可将本发明唾液酸以其药学可接受的盐的形态使用,也可将本发明唾液酸单独或适宜组合使用,还可与其他医药活性成分联合作为复合剂。
口服给药制剂中,可以单独或与适当的添加剂如赋形剂、黏合剂、崩解剂、润滑剂、增溶剂、润湿剂、缓衝剂、防腐剂、香料等适宜组合成片剂、散剂、颗粒剂或胶囊剂。而且,视疾病种类或患者,可制剂化为最适合其治疗的上述剂型以外的剂型,例如注射剂、栓剂、吸入剂、气雾剂、糖浆剂、滴眼剂、软膏等外用剂等。
本发明镇痛剂的理想给药量,可因给药对象、剂型、给药方法、给药期间等而有所不同,但为了达到预期效果,一般对成人来讲,日有效成分量为口服给药10至5,000mg,优选50至3,000mg。非口服给药(例如注射剂)时,一般比口服给药量更少而可期待有效果。
[实施例]
镇痛效力试验
使用神经性疼痛模型的Chung模型大鼠,实施镇痛效力试验。使用9周龄的Wistar系雄性大鼠作为实验动物,根据Kim及Chung的方法(Pain,50卷355-363页,1992年)作成模型大鼠。即,在10周龄时,以戊巴比妥(40mg/kg,腹腔给药)麻醉,露出大鼠L5脊髓神经,将L5后根神经节末梢侧以5-0丝纱强力扎紧进行神经损伤。将动物放在以金属网做底的透明压克力饲养箱中,使用von Frey纤维(filament) (North Coast Medical Inc.制),根据Chaplan等(J.Neurosci.Method,53卷,55-63页,1994年)的方法,以升降法(up-down method)算出50%反应阈值,测定针对被验物质的激痛效果。测定脊髓神经损伤后的50%反应阈值,以显示1g以上且未达4g的安定的阈值降低者用于试验。以这些实验动物神经损伤后的50%反应阈值做为指标,7只为1组,使神经损伤对照组与被验物质给药组的平均值几乎相等的方式构成组。
以N-乙酰基神经氨酸作为被验物质而单次在腹腔内给药(120mg/kg)。对神经损伤对照组(控制组)同样给药0.5%CMC-Na(w/v)/生理盐水,在被验物质给药30分钟后进行痛觉测验,算出50%反应阈值,各组以平均值±标准偏差表示。上述一例试验的结果示于表1。再者,差异明显性的检定,使用Dunnett多重检定比较法进行神经损伤对照组与被验物质给药组的多组间比较,而以P<0.05为有明显差异。
【表1】
*:P<0.05(Dunnett多重比较检定)
与上述试验同样,将N-乙酰基神经氨酸做为被验物质,单次口服(300mg/kg)给药。神经损伤对照组(控制组)则以注射用水同样给药,被验物质给药60分钟后进行痛觉测验,算出50%反应阈值。但是神经损害对照组与被验物质给药组各组的只数为8只。一例试验结果示于表2。
【表2】
*:P<0.05(Dunnett多重比较检定)
实施上述镇痛效力试验的结果,就单次腹腔内给药及单次口服给药两方面而言,关于神经损伤对照组(控制组),50%反应阈值在CMC-Na/生理盐水或注射用水给药前后都没有很大变化。相对的,被验物质(N-乙酰基神经氨酸)给药组的50%反应阈值,比神经损伤对照组的反应阈值有明显上升,可确认本发明化合物的抗激痛作用,即对神经性疼痛有明显镇痛作用。
(产业利用可能性)
如上述镇痛效力试验所示,唾液酸对神经性疼痛的病理模型动物具有明显镇痛作用。该神经性疼痛,与因炎症而产生的炎症性疼痛不同,为末梢神经或中枢神经本身的机能异常所引起而不伴随炎症疾病的痛。因此,本发明镇痛剂可用作治疗,例如,三叉神经痛、带状疱疹后神经痛、包埋性神经病变(胸廓出口综合症、腕管综合症、脊柱管狭窄症等)、复杂性局部痛综合症(CRPS),糖尿病性神经病变、外伤引起的神经障碍、幻肢痛、脊椎损伤后或脑中风后中枢疼痛,以及药物疗法或放射线治疗法引起的神经病变性痛等神经性疼痛疾病等非炎症性疼痛疾病的药剂。
Claims (3)
1.一种N-乙酰基神经氨酸或其药学可接受的盐的用途,其特征在于,所述用途为用于制造针对神经性疼痛的镇痛剂。
2.如权利要求1所述的用途,其特征在于,所述神经性疼痛为三叉神经痛、带状疱疹后神经痛、包埋性神经病变、复杂性局部痛综合症(CRPS)、糖尿病性神经病变、外伤引起的神经障碍、幻肢痛、中枢疼痛、或是药物疗法或放射线治疗法引起的神经性疼痛。
3.如权利要求1或2所述的用途,其特征在于,所述镇痛剂为口服剂。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007028721A JP4005115B1 (ja) | 2007-02-08 | 2007-02-08 | 疼痛疾患治療剤 |
JP028721/2007 | 2007-02-08 | ||
PCT/JP2008/051920 WO2008096775A1 (ja) | 2007-02-08 | 2008-02-06 | 疼痛疾患治療剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101600438A CN101600438A (zh) | 2009-12-09 |
CN101600438B true CN101600438B (zh) | 2012-06-27 |
Family
ID=38769833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008800039466A Expired - Fee Related CN101600438B (zh) | 2007-02-08 | 2008-02-06 | 疼痛疾病治疗剂 |
Country Status (9)
Country | Link |
---|---|
US (1) | US8492350B2 (zh) |
EP (1) | EP2119444B1 (zh) |
JP (1) | JP4005115B1 (zh) |
KR (1) | KR101472431B1 (zh) |
CN (1) | CN101600438B (zh) |
AU (1) | AU2008212250B2 (zh) |
CA (1) | CA2677026C (zh) |
TW (1) | TWI405576B (zh) |
WO (1) | WO2008096775A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014057995A1 (ja) | 2012-10-10 | 2014-04-17 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2116139A1 (en) * | 2008-05-08 | 2009-11-11 | Nestec S.A. | Sialic acid to support brain health in the elderly |
US20110301103A1 (en) * | 2010-06-05 | 2011-12-08 | Chugh Sumant S | Methods of Treatment |
US10039773B2 (en) | 2012-05-14 | 2018-08-07 | Antecip Bioventures Ii Llc | Neridronic acid for treating arthritis |
US9789128B2 (en) | 2012-05-14 | 2017-10-17 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9770457B2 (en) | 2012-05-14 | 2017-09-26 | Antecip Bioventures Ii Llc | Neridronic acid for treating bone marrow lesion |
US9895383B2 (en) | 2012-05-14 | 2018-02-20 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9795622B2 (en) | 2012-05-14 | 2017-10-24 | Antecip Bioventures Ii Llc | Neridronic acid for treating pain associated with a joint |
US10413560B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease |
US10463682B2 (en) | 2012-05-14 | 2019-11-05 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating low back pain |
US9820999B2 (en) | 2012-05-14 | 2017-11-21 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US10173986B2 (en) | 2012-05-14 | 2019-01-08 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
US10493085B2 (en) | 2012-05-14 | 2019-12-03 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
US9694023B2 (en) | 2012-05-14 | 2017-07-04 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
US9943531B2 (en) | 2014-08-08 | 2018-04-17 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
US10413561B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
US10111837B2 (en) | 2012-05-14 | 2018-10-30 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds |
US9877977B2 (en) | 2012-05-14 | 2018-01-30 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9700570B2 (en) | 2014-05-27 | 2017-07-11 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9925203B2 (en) | 2012-05-14 | 2018-03-27 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
US9956238B2 (en) | 2014-05-15 | 2018-05-01 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
US10092581B2 (en) | 2014-05-15 | 2018-10-09 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
US10028908B2 (en) | 2012-05-14 | 2018-07-24 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9867839B2 (en) | 2012-05-14 | 2018-01-16 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for joint conditions |
US9956237B2 (en) | 2012-05-14 | 2018-05-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
US10016445B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9211257B2 (en) | 2012-05-14 | 2015-12-15 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
US10028969B2 (en) | 2012-05-14 | 2018-07-24 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9999629B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9707245B2 (en) | 2012-05-14 | 2017-07-18 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US10004756B2 (en) | 2014-05-15 | 2018-06-26 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9782421B1 (en) | 2012-05-14 | 2017-10-10 | Antecip Bioventures Ii Llc | Neridronic acid molecular complex for treating complex regional pain syndrome |
US10016446B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone |
US11654152B2 (en) | 2012-05-14 | 2023-05-23 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
US10350227B2 (en) | 2012-05-14 | 2019-07-16 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US10080765B2 (en) | 2012-05-14 | 2018-09-25 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US9956234B2 (en) | 2012-05-14 | 2018-05-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for joint conditions |
US9901589B2 (en) | 2012-05-14 | 2018-02-27 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9844559B2 (en) | 2012-05-14 | 2017-12-19 | Antecip Bioventures Ii Llc | Neridronic acid for treating bone marrow lesions |
US9717747B2 (en) | 2012-05-14 | 2017-08-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
US9949993B2 (en) | 2012-05-14 | 2018-04-24 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
US9999628B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US9707247B2 (en) | 2012-05-14 | 2017-07-18 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
US9827192B2 (en) | 2012-05-14 | 2017-11-28 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9827256B2 (en) | 2014-05-27 | 2017-11-28 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating lower back pain |
US9861648B2 (en) | 2012-05-14 | 2018-01-09 | Antecip Boiventures Ii Llc | Osteoclast inhibitors for knee conditions |
US10034890B2 (en) | 2012-05-14 | 2018-07-31 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9867840B2 (en) | 2014-05-27 | 2018-01-16 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
JP5275502B1 (ja) * | 2012-10-10 | 2013-08-28 | 日本臓器製薬株式会社 | 抽出物及び製剤 |
JP5490939B2 (ja) * | 2013-04-19 | 2014-05-14 | 日本臓器製薬株式会社 | 抽出物及び製剤 |
JP5844320B2 (ja) * | 2013-08-23 | 2016-01-13 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
JP5844338B2 (ja) * | 2013-11-19 | 2016-01-13 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
US20140348916A1 (en) * | 2014-08-11 | 2014-11-27 | Antecip Bioventures Ii Llc | Treatment of Pain with Oral Dosage Forms Comprising Zoledronic Acid and An Enhancer |
SG11201705801VA (en) * | 2015-02-03 | 2017-08-30 | Atsuko Morita | Ingredient made from swiftlet nest as raw material, composition, and method for producing ingredient |
JP6043922B2 (ja) * | 2015-11-20 | 2016-12-14 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
KR101873527B1 (ko) | 2016-09-02 | 2018-07-02 | 부산대학교 산학협력단 | 시알산 유도체를 포함하는 자궁내막증 예방 또는 치료용 조성물 |
JP2016216518A (ja) * | 2016-09-28 | 2016-12-22 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1158571A (zh) * | 1995-05-25 | 1997-09-03 | 日本碍子株式会社 | 内毒素血症及由其诱发的多器官机能不全症的治疗药 |
CN1733096A (zh) * | 2005-08-10 | 2006-02-15 | 贵州老来福药业有限公司 | 黑骨藤伤湿贴及其制备方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1046051B (it) * | 1975-08-13 | 1980-06-30 | Fidia Spa | Nuova applicazione terapeutica dei gangliosidi e procedimento per la loro estrazione |
US4476119A (en) * | 1981-08-04 | 1984-10-09 | Fidia S.P.A. | Method for preparing ganglioside derivatives and use thereof in pharmaceutical compositions |
JPS6168418A (ja) | 1984-09-11 | 1986-04-08 | Kanto Ishi Pharma Co Ltd | 去痰薬 |
JPS62145015A (ja) | 1985-12-19 | 1987-06-29 | Kotobuki Chem:Kk | 抗炎症剤 |
IT1212041B (it) * | 1987-11-02 | 1989-11-08 | Fidia Farmaceutici | Gangliosidi esteri interni come agenti terapeutici capaci di eliminare il dolore nelle neuropatie periferiche |
JP2684179B2 (ja) | 1987-12-21 | 1997-12-03 | 雪印乳業株式会社 | 抗炎症剤 |
JP3286340B2 (ja) * | 1991-03-06 | 2002-05-27 | 日本臓器製薬株式会社 | シアル酸誘導体 |
US5438125A (en) * | 1991-03-06 | 1995-08-01 | Nippon Zoki Pharmaceutical Co., Ltd. | Sialic acid derivatives |
IT1260156B (it) * | 1992-08-03 | 1996-03-28 | Fidia Spa | Derivati dell'acido neuraminico |
JP4044630B2 (ja) * | 1996-05-16 | 2008-02-06 | 雪印乳業株式会社 | 脳機能改善剤 |
CN100400051C (zh) | 2004-12-15 | 2008-07-09 | 阿尔贝拉医药控股(通化)有限公司 | 一种药物组合物、其制备方法及其用途 |
CN1762486A (zh) | 2005-10-28 | 2006-04-26 | 诺氏制药(吉林)有限公司 | 脑苷肌肽在制备防治周围神经疾病药物中的用途 |
GB0614947D0 (en) * | 2006-07-27 | 2006-09-06 | Isis Innovation | Epitope reduction therapy |
-
2007
- 2007-02-08 JP JP2007028721A patent/JP4005115B1/ja not_active Expired - Fee Related
-
2008
- 2008-02-06 EP EP08704491.3A patent/EP2119444B1/en not_active Not-in-force
- 2008-02-06 WO PCT/JP2008/051920 patent/WO2008096775A1/ja active Application Filing
- 2008-02-06 CN CN2008800039466A patent/CN101600438B/zh not_active Expired - Fee Related
- 2008-02-06 AU AU2008212250A patent/AU2008212250B2/en not_active Ceased
- 2008-02-06 US US12/449,152 patent/US8492350B2/en not_active Expired - Fee Related
- 2008-02-06 CA CA2677026A patent/CA2677026C/en not_active Expired - Fee Related
- 2008-02-06 KR KR1020097014813A patent/KR101472431B1/ko active IP Right Grant
- 2008-02-12 TW TW097104808A patent/TWI405576B/zh not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1158571A (zh) * | 1995-05-25 | 1997-09-03 | 日本碍子株式会社 | 内毒素血症及由其诱发的多器官机能不全症的治疗药 |
CN1733096A (zh) * | 2005-08-10 | 2006-02-15 | 贵州老来福药业有限公司 | 黑骨藤伤湿贴及其制备方法 |
Non-Patent Citations (3)
Title |
---|
张德刚等.糖尿病周围神经病变的治疗.《临床荟萃》.2006,第21卷(第23期),1746-1747. * |
汪桐.疼痛与针感感受器及其传入神经.《皖南医学院学报》.1985,第4卷(第03期),221-224. * |
陈永权等.慢性脊神经痛患者脑脊液中神经节苷脂含量的变化.《中国疼痛医学杂志》.2001,(第01期),30-32. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014057995A1 (ja) | 2012-10-10 | 2014-04-17 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
Also Published As
Publication number | Publication date |
---|---|
EP2119444A1 (en) | 2009-11-18 |
AU2008212250B2 (en) | 2013-07-04 |
CA2677026C (en) | 2014-11-18 |
TWI405576B (zh) | 2013-08-21 |
US8492350B2 (en) | 2013-07-23 |
JP4005115B1 (ja) | 2007-11-07 |
WO2008096775A1 (ja) | 2008-08-14 |
EP2119444A4 (en) | 2010-06-09 |
US20100121040A1 (en) | 2010-05-13 |
KR20090107500A (ko) | 2009-10-13 |
AU2008212250A1 (en) | 2008-08-14 |
EP2119444B1 (en) | 2015-07-08 |
KR101472431B1 (ko) | 2014-12-12 |
JP2008189635A (ja) | 2008-08-21 |
CA2677026A1 (en) | 2008-08-14 |
CN101600438A (zh) | 2009-12-09 |
TW200838545A (en) | 2008-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101600438B (zh) | 疼痛疾病治疗剂 | |
US8017623B2 (en) | Dextromethorphan hydrochloride | |
Goldberg et al. | Multi-day low dose ketamine infusion for the treatment of complex regional pain syndrome | |
EA006598B1 (ru) | Композиция, содержащая трамадол и противосудорожное лекарственное средство | |
EP1977745B1 (en) | Treatment of incontinence | |
CN104784174A (zh) | 右美托咪定的药物新用途 | |
WO2005072725A1 (fr) | Utilisation de l-butylphtalide dans la fabrication de medicaments destines a prevenir et a traiter une maladie induite par l'ischemie cerebrale | |
CN1091441C (zh) | 甲磺酸氨氯地平及其制法和应用 | |
CN108703946B (zh) | 一种治疗糖尿病周围神经痛的透皮吸收制剂 | |
CN113679704B (zh) | 一种化合物在制备减轻神经性疼痛药物中的用途 | |
US4313937A (en) | Method for producing long-lasting analgesic effects of β-endorphin | |
RU2664693C1 (ru) | Способ предоперационной подготовки пациентов к офтальмологическим операциям | |
CN1187055C (zh) | 薯蓣皂甙元在制备治疗心肌缺血、心绞痛和心肌梗死的药物中的用途 | |
Nyholm et al. | Continuous intra-intestinal infusion of levodopacarbidopa in advanced Parkinson's disease | |
US10905674B2 (en) | Method of increasing melatonin synthesis to treat insomnia, ameliorate sleep disturbance and regulate sleep | |
CN101260063A (zh) | γ-氨基丁酸衍生物及其制备方法 | |
AU2023222825A1 (en) | Medication | |
CN103933034B (zh) | 一种含有木犀草素的药物组合物及应用 | |
RU2120283C1 (ru) | Способ лечения эпилепсии | |
EP2736501B1 (en) | Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol | |
JP2005527585A (ja) | 末梢神経系の疾患の治療のためのピリミジンヌクレオチドの使用 | |
CN102648915A (zh) | 一种治疗或预防神经病理性疼痛的药物组合物 | |
CN108420824A (zh) | 一种治疗糖尿病的产品及其制备与应用 | |
WO2015185990A1 (ru) | Способы получения двойных солей лоркасерина (варианты), продукты способов, двойные соли, фармацевтические композиции для лечения и/или профилактики нарушений, связанных с ожирением, их применение и способ лечения и/или профилактики нарушений, связанных с ожирением | |
UA11567U (en) | Method for correcting metabolic disorders in patients with metabolic syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120627 Termination date: 20220206 |
|
CF01 | Termination of patent right due to non-payment of annual fee |